Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Inclusion Criteria:

1. Diagnosis of at least 1 of the following:

• Hereditary angioedema (HAE) type I or II

• HAE with normal C1 inhibitor

• ACE-I-induced angioedema

• Non-histaminergic idiopathic angioedema

• Acquired angioedema.

2. Signed and dated written informed consent from the participant or, for participantsaged less than(<)18 years (or as per local regulation, such as <16 years in theUnited Kingdom [UK]), parent and/or participants legally authorized representative (LAR), and assent of the minor where applicable.

3. At sites only participating in the drug registry, participants must have taken atleast 1 dose of Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]).

4. Enrolled participants in Germany taking Firazyr (Icatibant) or Cinryze (C1 inhibitor [human]) will only use the respective product in accordance with the product label.

Exclusion Criteria:

1. Participants enrolled in clinical trials where the product is blinded or where theproduct under investigation is for the treatment of HAE, ACE-I-induced angioedema,non-histaminergic idiopathic angioedema, or acquired angioedema.

2. Participants enrolled in another Shire-sponsored registry involving products for thetreatment of HAE, ACE-I-induced angioedema, non-histaminergic idiopathic angioedema,or acquired angioedema. An exception applies to participants enrolled in the Shirelanadelumab ENABLE study.